Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds.
Eur J Med Chem
; 206: 112702, 2020 Nov 15.
Article
de En
| MEDLINE
| ID: mdl-32798789
ABSTRACT
SARS-CoV-2 3C-like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC50's of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Antiviraux
/
Inhibiteurs de protéases
/
Protéines virales non structurales
/
Betacoronavirus
/
Isatine
Limites:
Humans
Langue:
En
Journal:
Eur J Med Chem
Année:
2020
Type de document:
Article
Pays d'affiliation:
Chine